A Biotechnology Crossroads
By Becca Muir,
Science for the People
| 02. 01. 2021
Before Tina Stevens and Stuart Newman wrote Biotech Juggernaut, Newman helped Stevens fight legal action from an unexpectedly powerful adversary. Two scientists and the financer-author of Proposition 71, a 2004 California state initiative to fund stem cell medicine and promising imminent cures, wanted to prevent Stevens expressing her “false and misleading” views about the bill. Advocates said Proposition 71 would lead to miracle treatments for serious, debilitating illnesses such as Alzheimer’s, multiple sclerosis and heart disease. Using DNA from a patient and an egg donated by a healthy woman, researchers would produce embryonic stem cells that could then specialise and replace virtually any cell in the patient’s body.
But, Stevens, a bioethicist and historian, felt uneasy about the scientific and ethical claims of the proposition. She was part of a progressive wing of activists who were concerned about the serious risks posed to women who donated eggs for this research, as well as the troubling ethical implications of some of the techniques used. The type of stem cell research proposed in the proposition constituted a form of human cloning – somatic...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...